comparemela.com

Latest Breaking News On - Nantahala capital management - Page 22 : comparemela.com

Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $5.00 target price on the stock. Several other research firms have also commented on TSHA. Robert W. Baird boosted their price […]

Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $5 00 at Truist Financial

Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $5 00 at Truist Financial
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Elutia Inc announced that it expects to receive $10 5 million in funding from HighCape Partners Management, L P , Nantahala Capital Management, LLC and other investor

Elutia Inc. announced a private placement of 7,355,869 common shares and 11,033,804 pre funded warrants for the gross proceeds of $10.5 million on September 19, 2023. The transaction will include.

Logos Global Management LP Takes Position in Disc Medicine Opco Inc (NASDAQ:IRON)

Logos Global Management LP acquired a new stake in shares of Disc Medicine Opco Inc (NASDAQ:IRON – Free Report) in the first quarter, HoldingsChannel reports. The firm acquired 525,000 shares of the company’s stock, valued at approximately $11,125,000. Disc Medicine Opco accounts for approximately 1.6% of Logos Global Management LP’s holdings, making the stock its […]

Logos Global Management LP Decreases Stake in Ventyx Biosciences, Inc (NASDAQ:VTYX)

Logos Global Management LP lowered its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 58.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 270,000 shares of the company’s stock after selling 387,016 shares during the quarter. Ventyx Biosciences accounts […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.